ezetimibe has been researched along with Blood Clot in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Antoku, Y; Egashira, K; Honda, K; Ichi, I; Koga, JI; Matoba, T; Nakano, K; Tsutsui, H | 1 |
Fazio, S; Weitz, JI | 1 |
Baigent, C; Blackwell, L; Emberson, J; Fellström, B; Haynes, R; Herrington, W; Hooi, LS; Landray, MJ; Levin, A; Massy, ZA; Reith, C; Staplin, N; Tesar, V; Walker, R | 1 |
Adamska, U; Adamski, P; Koziński, M; Kubica, J; Ostrowska, M | 1 |
Abela, GS; Abela, OG; Aziz, K; Berger, K; Janoudi, A; Patel, R; Rubinstein, J; Tamhane, U; Vedre, A | 1 |
1 review(s) available for ezetimibe and Blood Clot
Article | Year |
---|---|
New directions for pharmacotherapy in the treatment of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Antibodies, Monoclonal; Anticholesteremic Agents; Clinical Trials as Topic; Drug Discovery; Ezetimibe; Humans; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Treatment Outcome | 2016 |
1 trial(s) available for ezetimibe and Blood Clot
Article | Year |
---|---|
The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection.
Topics: Aged; Anticholesteremic Agents; Azetidines; Catheterization; Cholesterol, LDL; Device Removal; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Reoperation; Simvastatin; Thrombosis; Vascular Access Devices; Vascular Patency | 2014 |
3 other study(ies) available for ezetimibe and Blood Clot
Article | Year |
---|---|
Lipid-Lowering Therapy With Ezetimibe Decreases Spontaneous Atherothrombotic Occlusions in a Rabbit Model of Plaque Erosion: A Role of Serum Oxysterols.
Topics: Angiotensin II; Animals; Anticholesteremic Agents; Arterial Occlusive Diseases; Atherosclerosis; Biomarkers; Cells, Cultured; Cholesterol, Dietary; Diet, High-Fat; Disease Models, Animal; Down-Regulation; Ezetimibe; Femoral Artery; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Oxysterols; Plaque, Atherosclerotic; Rabbits; Rats; Rosuvastatin Calcium; Signal Transduction; Thrombosis; Vascular System Injuries | 2018 |
Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis.
Topics: Anticholesteremic Agents; Aspirin; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Plaque, Atherosclerotic; Rivaroxaban; Thrombosis | 2019 |
Plaque rupture and thrombosis are reduced by lowering cholesterol levels and crystallization with ezetimibe and are correlated with fluorodeoxyglucose positron emission tomography.
Topics: Animals; Anticholesteremic Agents; Aorta; Azetidines; C-Reactive Protein; Cholesterol; Crystallization; Ezetimibe; Fluorodeoxyglucose F18; Male; Plaque, Atherosclerotic; Positron-Emission Tomography; Rabbits; Radiopharmaceuticals; Thrombosis | 2011 |